Skip to main content
Premium Trial:

Request an Annual Quote

Needs 'Careful Scrutiny'

The coronavirus vaccine being developed by AstraZeneca and Oxford University will likely not be ready for distribution by late December, the Guardian reports.

Oxford's Andrew Pollard, who is heading up the trial, told the science and health committees of the UK House of Commons that it is difficult to determine exactly when the vaccine could be used to vaccinate people, according to the Guardian. It adds that he said he thinks that there will be enough data by then to analyze, but that regulatory authorities will then have to also go through the numbers. "We absolutely need that to happen so there's very careful scrutiny of everything that's been done in the clinical trials, to look at their integrity and the quality of the data and to verify that the results are correct," Pollard told the committees, according to the Guardian.

The candidate vaccine under testing from AstraZeneca and Oxford targets the viral spike protein, and is being investigated at trial sites in the UK, US, Brazil, South Africa, and other spots. The trial was paused in September when a participant in the UK experienced a possible adverse effect, but resumed shortly thereafter in the UK and other locales, but did not restart in the US until late October.